ERBB2 and neoplasm: Patients with advanced GC who have undergone HER‐2 overexpression as a result of gene amplification in their tumor cells have been demonstrated to have an elevated chance of survival when treated with the monoclonal antibody trastuzumab, which targets HER‐2.